<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">IJID Reg</journal-id><journal-id journal-id-type="iso-abbrev">IJID Reg</journal-id><journal-title-group><journal-title>IJID Regions</journal-title></journal-title-group><issn pub-type="epub">2772-7076</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786080</article-id><article-id pub-id-type="pii">S2772-7076(24)00229-7</article-id><article-id pub-id-type="doi">10.1016/j.ijregi.2024.100560</article-id><article-id pub-id-type="publisher-id">100560</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Report</subject></subj-group></article-categories><title-group><article-title>Prevalence and molecular characterization of hepatitis delta virus infection among hepatitis B virus surface antigen positive students and pregnant women in N'djamena, Chad</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>Debsikr&#x000e9;o</surname><given-names>Nalda</given-names></name><email>ndaldaeliane@gmail.com</email><xref rid="aff0001" ref-type="aff">1</xref><xref rid="aff0002" ref-type="aff">2</xref><xref rid="aff0003" ref-type="aff">3</xref><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>Dehainsala</surname><given-names>Maire</given-names></name><xref rid="aff0004" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au0003"><name><surname>Debsikr&#x000e9;o</surname><given-names>Odan</given-names></name><xref rid="aff0005" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au0004"><name><surname>Leye</surname><given-names>Nafissatou</given-names></name><xref rid="aff0002" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au0005"><name><surname>LO</surname><given-names>Gora</given-names></name><xref rid="aff0002" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au0006"><name><surname>Dia</surname><given-names>Aminata</given-names></name><xref rid="aff0002" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au0007"><name><surname>Flore</surname><given-names>Makoutchouang Nzonde Biscotine</given-names></name><xref rid="aff0001" ref-type="aff">1</xref><xref rid="aff0002" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au0008"><name><surname>Diaw</surname><given-names>Ndeye Aminata</given-names></name><xref rid="aff0002" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au0009"><name><surname>Diouf</surname><given-names>Ndeye Dieynaba</given-names></name><xref rid="aff0002" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au0010"><name><surname>Otchere</surname><given-names>Isaac Darko</given-names></name><xref rid="aff0006" ref-type="aff">6</xref><xref rid="aff0007" ref-type="aff">7</xref></contrib><contrib contrib-type="author" id="au0011"><name><surname>Toy&#x000e9;</surname><given-names>Rayana Maryse</given-names></name><xref rid="aff0008" ref-type="aff">8</xref></contrib><contrib contrib-type="author" id="au0012"><name><surname>Chemin</surname><given-names>Isabelle</given-names></name><xref rid="aff0008" ref-type="aff">8</xref></contrib><contrib contrib-type="author" id="au0013"><name><surname>Moussa</surname><given-names>Ali Mahamat</given-names></name><xref rid="aff0003" ref-type="aff">3</xref><xref rid="aff0004" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au0014"><name><surname>Toure-Kane</surname><given-names>Nd&#x000e8;ye Coumba</given-names></name><xref rid="aff0002" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au0015"><name><surname>Lunel-Fabiani</surname><given-names>Fran&#x000e7;oise</given-names></name><xref rid="aff0009" ref-type="aff">9</xref></contrib><aff id="aff0001"><label>1</label>Cheikh Anta Diop University, Dakar, Senegal</aff><aff id="aff0002"><label>2</label>Institut de Recherche en Sant&#x000e9;, de Surveillance &#x000c9;pid&#x000e9;miologique et de Formation, Dakar, S&#x000e9;n&#x000e9;gal</aff><aff id="aff0003"><label>3</label>University of N'Djamena, N'Djamena, Chad</aff><aff id="aff0004"><label>4</label>Centre Hospitalier Universitaire la R&#x000e9;f&#x000e9;rence, N'Djamena, Chad</aff><aff id="aff0005"><label>5</label>University of F&#x000e9;lix Houphou&#x000eb;t Boigny Abidjan, Abidjan, C&#x000f4;te d'ivore</aff><aff id="aff0006"><label>6</label>Medical Research Council Unit the Gambia at London School of Hygiene and Tropical Medicine, Fajara, the Gambia</aff><aff id="aff0007"><label>7</label>Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana</aff><aff id="aff0008"><label>8</label>Centre de Recherche en Canc&#x000e9;rologie de Lyon INSERM U1052, CNRS UMR5286, Universit&#x000e9; de Lyon, Lyon, France</aff><aff id="aff0009"><label>9</label>Centre Hospitalier Universitaire Angers, BAT IBS-4 rue Larrey-49000 ANGERS, Laboratoire HIFIH, UFR Sant&#x000e9; d&#x000e9;partement M&#x000e9;decine, SFR 4208-UPRES EA3859, Universit&#x000e9; d'Angers, Angers Cedex, France</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#x0204e;</label>Corresponding author: <email>ndaldaeliane@gmail.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>28</day><month>12</month><year>2024</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>12</month><year>2024</year></pub-date><volume>14</volume><elocation-id>100560</elocation-id><history><date date-type="received"><day>4</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract abstract-type="author-highlights" id="abs0001"><title>Highlights</title><p><list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>&#x02022;</label><p id="para0001">First genotypic characterization of the hepatitis D virus (HDV) among pregnant women and students in Chad.</p></list-item><list-item id="celistitem0002"><label>&#x02022;</label><p id="para0002">Confirmation of combined presence of hepatitis B virus-E and HDV-1 among co-infected patients.</p></list-item><list-item id="celistitem0003"><label>&#x02022;</label><p id="para0003">High seroprevalence of HDV among pregnant women in Chad.</p></list-item></list></p></abstract><abstract id="abs0002"><sec><title>Objectives</title><p>This study sought to determine the prevalence of hepatitis B virus (HBV)-hepatitis D virus (HDV) co-infection and to characterize isolates of both viruses in a Chadian population of HBV surface antigen (HBsAg)-positive pregnant women and students.</p></sec><sec><title>Methods</title><p>This was a cross-sectional retrospective study using archived samples from pregnant women and students in N'djamena who had been systematically screened for HBsAg between April and August 2021. HBsAg-positive samples were tested for the presence of HDV antibodies (Ab) and were screened for the presence of both HBV and HDV (in anti-HDV Ab-positive samples) viral load estimations. Genome sequencing of the viruses was used for both genotyping and phylogenetic analysis.</p></sec><sec><title>Results</title><p>A total of 94 participants were included in this study. The mean age was 24 &#x000b1; 4.89 years (range: 18-42 years). Anti-HDV Ab were found in 9.57% (9/94) of the participants. The prevalence of anti-HDV Ab positivity among students (6.45% [4/62]) was lower than the 15.63% (5/32) observed among pregnant women. HDV-RNA was detected in 7/9 (77.77%) confirmed anti-HDV-positive participants. Most HDV-RN-positive participants had very low HBV DNA viral loads. All HBV sequences belonged to genotype E and all HDV sequences to genotype 1.</p></sec><sec><title>Conclusions</title><p>Hepatitis D is a potential public health challenge in Chad, which requires active surveillance and public education in the country for proper control. This surveillance should be supported with mass immunization against HBV.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Hepatitis D virus</kwd><kwd>Genotype</kwd><kwd>Prevalence</kwd><kwd>Students</kwd><kwd>Pregnant women</kwd><kwd>Chad and Africa</kwd></kwd-group></article-meta></front><body><sec id="sec0001"><title>Introduction</title><p id="para0008">Hepatitis D virus (HDV) is a hepatotropic virus, a negative-sense circular single-stranded RNA virus of approximately 1.7 kb, and is the only member of the <italic>Deltaviridae</italic> family (genus Deltavirus) [<xref rid="bib0001" ref-type="bibr">1</xref>]. HDV requires hepatitis B virus (HBV) surface proteins (HBsAg) to form infectious viral particles [<xref rid="bib0002" ref-type="bibr">2</xref>]. Without HBV, the HDV is incapable of penetrating hepatocytes and replicating itself [<xref rid="bib0003" ref-type="bibr">3</xref>]. HDV causes acute and chronic liver disease [<xref rid="bib0004" ref-type="bibr">4</xref>] and an increased risk of hepatocellular carcinoma [<xref rid="bib0005" ref-type="bibr">5</xref>].</p><p id="para0009">Delta hepatitis is still a major global health problem affecting 48-60 million individuals worldwide [<xref rid="bib0006" ref-type="bibr">6</xref>]. It is estimated that 7.33% of HBsAg carriers are co-infected or superinfected with HDV in the general population, whereas 9.57% of people with liver disease in West Africa are also infected with HDV [<xref rid="bib0007" ref-type="bibr">7</xref>]. In Central Africa, it is 25.64% of the general population and 37.77% among people with liver disease [<xref rid="bib0007" ref-type="bibr">7</xref>,<xref rid="bib0008" ref-type="bibr">8</xref>].</p><p id="para0010">In addition to Central Africa, regions, including Northern Africa [<xref rid="bib0007" ref-type="bibr">7</xref>], the Amazon basin, Eastern Europe, the Mediterranean countries, the Middle East, and certain regions of Asia, are regions with a high endemicity of HDV [<xref rid="bib0009" ref-type="bibr">9</xref>]. Besides its co-existence with HBV, the HDV genotypes or subtypes may have variable levels of virulence, such as the risk of developing chronic infection. Currently, HDV has eight distinct genotypes, each with two to four subtypes, with a sequence disparity of approximately 35% between genotypes. The predominant genotype in a geographic region varies with genetic diversity between and within genotypes [<xref rid="bib0010" ref-type="bibr">10</xref>]. Genotype 1 is the most widespread and predominates in Europe and North America. Genotype 2 is most widespread in Asia and the Middle East. Compared with genotype 2, genotype 1 has a higher risk of adverse effects and lower remission rates [<xref rid="bib0011" ref-type="bibr">11</xref>]. Genotype 3 is associated with severe liver disease, found in the Amazon basin, and is different from the other genotypes. Genotype 4 is found in Taiwan and China. Genotypes 5, 6, 7, and 8 are predominant in Africa and can also be found in Europe [<xref rid="bib0012" ref-type="bibr">12</xref>].</p><p id="para0011">HDV is mainly transmitted parenterally through blood exposure, unprotected sexual intercourse, or blood products, making mother-to-child transmission very rare [<xref rid="bib0013" ref-type="bibr">13</xref>]. A person may either be simultaneously co-infected with the two hepatitis viruses or be a carrier of HBV prior to exposure to HDV, which is referred to as superinfection [<xref rid="bib0014" ref-type="bibr">14</xref>]. Co-infection or superinfection may lead to fulminant forms or severe chronic course of the disease. It can change the course of asymptomatic or inactive HBV infection into chronic active hepatitis, favoring the development of severe liver lesions and rapid progression to liver cirrhosis and hepatocellular carcinoma [<xref rid="bib0015" ref-type="bibr">15</xref>].</p><p id="para0012">Even though seroprevalence of HDV antibodies (anti-HDV) is 14% among chronic HBsAg carriers in N'Djamena hospitals [<xref rid="bib0016" ref-type="bibr">16</xref>], information regarding the circulating genotypes of HDV is scarcely available in Chad.</p><p id="para0013">Therefore, we sought to determine the prevalence of HDV in a population of HBsAg-positive pregnant women and students using archived samples from previous studies in Chad [<xref rid="bib0017" ref-type="bibr">17</xref>,<xref rid="bib0018" ref-type="bibr">18</xref>] and characterize the detected HBV and HDV.</p></sec><sec id="sec0002"><title>Methods</title><sec id="sec0003"><title>Study population</title><p id="para0014">This was a retrospective cross-sectional survey of 457 students (both males and females) from the University of N'djamena (public institution) and Emi Koussi University (private institution in N'djamena) Chad from July 3 to July 23, 2021 [<xref rid="bib0017" ref-type="bibr">17</xref>] and 458 pregnant women from eight gynecology and obstetrics departments of hospitals in N'djamena [<xref rid="bib0018" ref-type="bibr">18</xref>]. The inclusion criteria for recruitment are already described in the earlier publications [<xref rid="bib0017" ref-type="bibr">17</xref>,<xref rid="bib0018" ref-type="bibr">18</xref>]. We used only the archived samples from these studies for our study. After taking out seven samples with insufficient sample volume, 94 frozen sera samples positive for HBsAg from 47 males (all students) and 47 females (comprising 15 students and 32 pregnant women) stored at &#x02212;80 &#x000b0;C in the biobank laboratory of the National Reference Hospital were sent to the &#x0201c;Institut de Recherche en Sant&#x000e9;, de Surveillance Epid&#x000e9;miologique et de Formation&#x0201d; (IRESSEF) in Senegal and INSERM U1052 in France for further analysis.</p></sec><sec id="sec0004"><title>Serologic assays</title><p id="para0015">Serologic tests were performed at the virology laboratory of the IRESSEF. HBsAg positivity was confirmed using the Abbott Architect i1000SR analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA), and quantification of HDV antibodies (HDV-Ab) was determined using ETI-AB-DELTAK-2 kits (Diasorin, Italy).</p><sec id="sec0005"><title>Nucleic acid extraction</title><p id="para0016">DNA was extracted using the MagMAXTM Viral/Pathogen II Nucleic Acid Kit on the KingFisher&#x02122; Flex automated system from Thermo Scientific&#x02122;, according to the manufacturer's instructions. HBV-DNA and HDV-RNA extractions from samples received at INSERM were performed using the High Pure viral nucleic acid kit (Roche), according to the manufacturer's instructions. The technique requires a volume of 200 &#x000b5;l of serum or plasma, and the nucleic acids were eluted in a final volume of 50 &#x000b5;l.</p></sec><sec id="sec0006"><title>Quantification of hepatitis B virus and hepatitis B virus genotyping</title><p id="para0017">HBV viral load was determined using the GeneProof HBV polymerase chain reaction (PCR) kit with sensitivity up to 13.9 IU/ml and 100% diagnostic sensitivity [<xref rid="bib0019" ref-type="bibr">19</xref>]. Viral DNA of HBV samples had 1200 nt HBV S gene amplified by semi-nested PCR, using the GoTaq&#x000ae; G2 Flexi DNA Polymerase Kit. Two primer pairs, F8 /R5 and F3/R8, were used for PCR 1 and PCR 2 amplification, respectively. The cycling conditions were five initial denaturation at 94 &#x000b0;C, followed by 40 cycles of denaturation at 94 &#x000b0;C for 30 seconds, annealing at 42 &#x000b0;C for 30 seconds, and primer extension at 72 &#x000b0;C for 1 minute before final extension of the amplified DNA at 72 &#x000b0;C for 7 minutes. The PCR products were then visualized on 1.5% agarose gel under ultra violet illumination after staining with ethidium bromide.</p></sec><sec id="sec0007"><title>Quantification of hepatitis D virus and hepatitis D virus genotyping</title><p id="para0018">HDV viral loads (VL) were determined at the Centre de Recherche en Canc&#x000e9;rologie de Lyon INSERM U1052 laboratory (France) using ddPCR and reverse transcription-ddPCR (Biorad). One-step quantitative reverse transcription-PCR was performed using the Quantitect Virus kit (Qiagen, Courtaboeuf, France), following the manufacturer's instructions. Co-amplification of CI and HDV RNAs occurred in the same tube. CI detection was performed using the Quasar 670 labeled probe and primers provided in the kit (Simplexa Extraction and Amplification Control Set-RNA; Focus Diagnostics, Cypress, California, and Eurobio, Les Ulis, France) using two direct primers (AgD-F1, AgD-F2) and one reverse primer (AgD-R), following the previously described amplification conditions [<xref rid="bib0020" ref-type="bibr">20</xref>].</p></sec><sec id="sec0008"><title>Sequencing and phylogenetic analyses</title><p id="para0019">To determine HVB and HDV isolates, the HBV <italic>S</italic> gene (1200 nt) and the HDV <italic>R0</italic> region (400 nt) were sequenced by Sanger from purified PCR fragments. The sequenced genetic elements were mapped to respective HBV and HDV reference sequences using the multiple alignment fast Fourier transform (MAFFT) tool. We performed a model test and constructed a phylogenetic tree based on the maximum likelihood method with 1000 bootstrap replicates using the MEGA 7 software.</p><p id="para0020">For alignment and HDV genotyping, prototype HDV-sequences retrieved from the NCBI GenBank were used HDV-1: LS482933, JX888110, JX888098, JX888105, JX888108, U81989, LT604946, KJ744227, MH457142, AM779579, L22066, AM902175, MG711717, MG711801, JX888109, MG711713, MG711667, JN187436; HDV-2: L19598, LT604953; HDV-3: L22063, KC590319; HDV-4: AB118841, AB088679; HDV-5: JX888107, U19598; HDV-6: JX888102, LT604968; HDV-7: AM183333, LT604972, and HDV-8: LT604973, LT604974.</p><p id="para0021">For alignment and HBV-genotyping, HBV-genotype sequences retrieved from the NCBI GenBank were used HBV genotype A: EU694385, KP168423, GQ331046, KM606737, AM184126, FJ692601; genotype B: D23679, JQ801514; genotype C: DQ089781, KC774182; genotype D: AB222711, MF925358; genotype E: KF170742, MT426116, MG621119, MG821154, GQ161817, GQ161772, DQ060824, JQ000008, DQ060822, AJ605008, AM494689; genotype F: HM585194, DQ899143; genotype G: AB056513; genotype H: FJ356715, and genotype I: AB562463; FJ023669.</p></sec></sec><sec id="sec0009"><title>Statistical analysis</title><p id="para0022">The obtained data were entered into Microsoft Excel and imported into STATA version 12.1 for data analysis. Quantitative variables were expressed as mean &#x000b1; SD. Categoric variables were expressed as numbers and percentages and compared using chi-square or Fisher's exact test when appropriate, whereas the independent <italic>t</italic>-test was used to compare the means of continuous variables. When normal distribution or equal variance could not be assumed, the Mann-Whitney U test was used. With a 95% confidence interval (CI), <italic>P</italic>-values &#x0003c;0.05 were considered statistically significant.</p></sec></sec><sec id="sec0010"><title>Results</title><sec id="sec0011"><title>Characteristics of the study population</title><p id="para0023">As shown below (<xref rid="tbl0001" ref-type="table">Table 1</xref>), a total of 94 samples from 62 students and 32 pregnant women described elsewhere [<xref rid="bib0017" ref-type="bibr">17</xref>,<xref rid="bib0018" ref-type="bibr">18</xref>] (mean age 24.39 &#x000b1; 4.89 years) were included in this study. In addition to the 32 pregnant women, there were 15 females among the students whose samples were used for this study, given a 1:1 ratio. Whereas all the pregnant (100%) women were married, only 16 (25.8%) of the students were married. Seventy-one (75.53%) of the participants had had unprotected sex, 25 (26.60%) had HBsAg-positive mothers, and other potential risk factors for HBV/HDV infection, including family history of HBV, blood transfusions, transcutaneous medical examinations, and injecting drugs.<table-wrap position="float" id="tbl0001"><label>Table 1</label><caption><p>Participant's sociodemographic characteristics and history.</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Variable</th><th valign="top">Pregnant women<break/>n = 32</th><th valign="top">Student<break/>n = 62</th><th valign="top">Total cohort<break/>n = 94</th></tr></thead><tbody><tr><td valign="top">Age</td><td valign="top">Mean = 25</td><td valign="top">Mean = 23</td><td valign="top">Mean = 24.39 (&#x000b1; 4.89)</td></tr><tr><td valign="top">18-24</td><td valign="top">15 (46.88)</td><td valign="top">42/62 (67.74)</td><td valign="top">57 (60.64)</td></tr><tr><td valign="top">25-34</td><td valign="top">11 (34.38)</td><td valign="top">20/62 (32.26)</td><td valign="top">31 (32.98)</td></tr><tr><td valign="top">&#x02265;35</td><td valign="top">6 (18.75)</td><td valign="top">0/62 (0.00)</td><td valign="top">6 (6.38)</td></tr><tr><td valign="top">Gender</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Male</td><td valign="top">0 (00.00%)</td><td valign="top">47 (75.81)</td><td valign="top">47 (50.00)</td></tr><tr><td valign="top">Female</td><td valign="top">32/32 (100.00)</td><td valign="top">15 (24.19)</td><td valign="top">47 (50.00)</td></tr><tr><td valign="top">Marital status</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Single</td><td valign="top">0/32 (0.00)</td><td valign="top">46/62 (74.19)</td><td valign="top">46 (48.94)</td></tr><tr><td valign="top">Married</td><td valign="top">32/32 (100.00)</td><td valign="top">16/62 (25.81)</td><td valign="top">48 (51.06)</td></tr><tr><td valign="top">Potential risk factors</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Blood transfusions</td><td valign="top">12/32 (12.50)</td><td valign="top">10/62 (16.13)</td><td valign="top">14/94 (14.89)</td></tr><tr><td valign="top">Hospital admission</td><td valign="top">8/32 (25.00)</td><td valign="top">13/62 (20.97)</td><td valign="top">21/62 (22.34)</td></tr><tr><td valign="top">Mother hepatitis B surface antigen positive</td><td valign="top">4/32 (12.50)</td><td valign="top">21/62 (33.87&#x000b0;</td><td valign="top">25/94 (26.60)</td></tr><tr><td valign="top">Family history hepatitis B virus</td><td valign="top">2/32 (6.25)</td><td valign="top">13/62 (20.97)</td><td valign="top">15/94 (15.96)</td></tr><tr><td valign="top">Transcutaneous medical examinations</td><td valign="top">0/32 (00.00)</td><td valign="top">16/62 (25.81)</td><td valign="top">16/94 (17.02)</td></tr><tr><td valign="top">Unprotected sex</td><td valign="top">31/32 (96.88)</td><td valign="top">20/62 (64.52)</td><td valign="top">71/94 (75.53)</td></tr><tr><td valign="top">Injection drugs</td><td valign="top">0/32 (00.00)</td><td valign="top">1/62 (1.61)</td><td valign="top">1/94 (1.06)</td></tr><tr><td valign="top">Jail</td><td valign="top">1/32 (3.13)</td><td valign="top">5/62 (8.06)</td><td valign="top">6/94 (6.38)</td></tr></tbody></table></table-wrap></p></sec><sec id="sec0012"><title>Anti-hepatitis D virus antibodies seroprevalence and associated risk factors</title><p id="para0024">The HDV prevalence (anti-HDV antibodies) of the total cohort was 9.57% (9/64), whereas that of the students and the pregnant women was 6.45% (4/62) and 15.63% (5/32), respectively (<xref rid="tbl0002" ref-type="table">Table 2</xref>).<table-wrap position="float" id="tbl0002"><label>Table 2</label><caption><p>Prevalence of hepatitis D virus among participants.</p></caption><alt-text id="alt0002">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Variable</th><th valign="top">Categories</th><th colspan="2" align="left" valign="top">Anti-hepatitis D virus antibodies<hr/></th><th valign="top">Crude odds ratio</th><th valign="top"><italic>P</italic> (95% confidence interval)</th></tr><tr><th valign="top"/><th valign="top"/><th valign="top">Negative</th><th valign="top">Positive</th><th valign="top"/><th valign="top"/></tr></thead><tbody><tr><td valign="top">Cohort</td><td valign="top">Pregnant women</td><td valign="top">27 (84.38)</td><td valign="top">5 (15.63)</td><td valign="top">0.37</td><td valign="top">0.265 (0.09-1.49)</td></tr><tr><td valign="top"/><td valign="top">Student</td><td valign="top">58 (93.55)</td><td valign="top">4 (6.45)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Age</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">1.31</td><td valign="top">0.607 (0.45-3.77)</td></tr><tr><td valign="top"/><td valign="top">18-24</td><td valign="top">52 (91.23)</td><td valign="top">5 (8.77)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top">25-34</td><td valign="top">28 (90.32)</td><td valign="top">3 (9.68)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top">&#x02265;35</td><td valign="top">5 (83.33)</td><td valign="top">1 (16.67)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Gender</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">0.78</td><td valign="top">1.000 (0.19-3.11)</td></tr><tr><td valign="top"/><td valign="top">Female</td><td valign="top">42 (89.36)</td><td valign="top">5 (10.64)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Male</td><td valign="top">43 (91.49)</td><td valign="top">4 (8.51)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Marital situation</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">1.22</td><td valign="top">1.000 (0.30-4.86)</td></tr><tr><td valign="top"/><td valign="top">Single</td><td valign="top">42 (91.30)</td><td valign="top">4 (8.70)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Married</td><td valign="top">43 (89.58)</td><td valign="top">5 (10.42)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Blood transfusions</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">1.73</td><td valign="top">0.618 (0.32-9.38)</td></tr><tr><td valign="top"/><td valign="top">No</td><td valign="top">73 (91.25)</td><td valign="top">7 (8.75)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Yes</td><td valign="top">12 (85.71)</td><td valign="top">2 (9.57)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Hospital admission</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">0.40</td><td valign="top">0.678 (0.04-3.44)</td></tr><tr><td valign="top"/><td valign="top">No</td><td valign="top">65 (89.04)</td><td valign="top">8 (10.96)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Yes</td><td valign="top">20 (95.24)</td><td valign="top">1 (4.76)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Hepatitis B surface antigen positive mother</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">1.25</td><td valign="top">0.656 (0.47-3.33)</td></tr><tr><td valign="top"/><td valign="top">No</td><td valign="top">55 (91.67)</td><td valign="top">5 (8.33)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Yes</td><td valign="top">22 (88.00)</td><td valign="top">3 (12.00)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Family history hepatitis B virus</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">0.37</td><td valign="top">0.191 (0.11-1.28)</td></tr><tr><td valign="top"/><td valign="top">No</td><td valign="top">46 (85.19)</td><td valign="top">8 (14.81)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Yes</td><td valign="top">15 (100.00)</td><td valign="top">0 (0.00)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Transcutaneous medical examinations</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">NA</td><td valign="top">NA</td></tr><tr><td valign="top"/><td valign="top">No</td><td valign="top">69 (88.46)</td><td valign="top">9(11.54)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Yes</td><td valign="top">16 (100.00)</td><td valign="top">0 (0.00)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Unprotected sex</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">2.79</td><td valign="top">0.445 (0.33-23.62)</td></tr><tr><td valign="top"/><td valign="top">No</td><td valign="top">22 (95.65)</td><td valign="top">1 (4.35)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Yes</td><td valign="top">63 (88.73)</td><td valign="top">8 (11.27)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Injection drugs</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">NA</td><td valign="top">NA</td></tr><tr><td valign="top"/><td valign="top">No</td><td valign="top">85 (91.40)</td><td valign="top">8 (8.60)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Yes</td><td valign="top">0 (0.00)</td><td valign="top">1 (100.00)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Jail</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">NA</td><td valign="top">NA</td></tr><tr><td valign="top"/><td valign="top">No</td><td valign="top">79 (89.77)</td><td valign="top">9 (10.23)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Yes</td><td valign="top">6 (100.00)</td><td valign="top">0 (0.00)</td><td valign="top"/><td valign="top"/></tr></tbody></table></table-wrap></p></sec><sec id="sec0013"><title>Detection and quantification of hepatitis B virus DNA and hepatitis D virus RNA</title><p id="para0025">HBV DNA was detected in 52 of the 94 HBsAg-positive cases (55.31%) and HDV RNA in 7/9 (77.77%) of the anti-HDV-Ab-positive participants. The median HDV viral load (VL) was 2.63 log10 copies/ml (1.18-3.22), with only one sample having a VL greater than 3 log10 copies/ml with three samples having a VL greater than 3 log10 copies/ml (<xref rid="fig0001" ref-type="fig">Figure 1</xref>).<fig id="fig0001"><label>Figure 1</label><caption><p>Flow chart of study participants.</p></caption><alt-text id="alt0003">Figure 1</alt-text><graphic xlink:href="gr1" id="celink0001"/><attrib>HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HDV, hepatitis D virus.</attrib></fig></p></sec><sec id="sec0014"><title>Hepatitis B virus and hepatitis D virus genotypes</title><p id="para0026">HBV genotyping was successfully performed for three samples, including those from one pregnant woman and two male students. The model test showed that the best substitution model with the lowest Bayesian information criterion (BIC) score was the Kimura-2 parameter using a discrete Gamma distribution with five rate categories (K2+G). The phylogenetic tree comprised our three sequences and 31 HBV reference sequences from all genotypes (34 sequences in total). <xref rid="fig0002" ref-type="fig">Figure 2</xref> shows that all HBV sequences from Chad belong to genotype E. Indeed, our sequences clustered close to HBV genotype E reference sequences with a very high bootstrap value (99%) and closer to genotype E sequences from neighboring countries, including Sudan, Nigeria, and Cameroon.<fig id="fig0002"><label>Figure 2</label><caption><p>Maximum likelihood phylogenetic tree of Chadian HBV.</p></caption><alt-text id="alt0004">Figure 2</alt-text><graphic xlink:href="gr2" id="celink0002"/><attrib>Isolates (981 nucleotides) and HBV genotypes A to J reference sequences retrieved from the GenBank database. The evolutionary history was inferred using the maximum likelihood method based on the Kimura 2-parameter (K2) model. Samples sequenced in this study are identified by the prefix TC. Reference sequences are identified by their accession number, country of origin, and (sub) genotype. The numbers at each node correspond to the bootstrap values (&#x0003e;70%) obtained with 1000 replicates. HBV, hepatitis B virus.</attrib></fig></p><p id="para0027">HDV genotyping was successful in six samples, including three pregnant women, one female student, and two male students. The model test showed that the best substitution model with the lowest BIC score was the Tamura-3 parameter using a discrete Gamma distribution with five rate categories (T92+G). The phylogenetic tree comprised our six sequences and 33 HDV reference sequences from all genotypes (39 sequences in total). <xref rid="fig0003" ref-type="fig">Figure 3</xref> shows that all HDV sequences from Chad belong to genotype 1. Indeed, our sequences clustered close to HDV genotype 1 reference sequences with a very high bootstrap value (98%) and closer to genotype 1 sequences from neighboring countries, including Cameroon, Nigeria, Central African Republic (CAR), and Gabon.<fig id="fig0003"><label>Figure 3</label><caption><p>Maximum likelihood phylogenetic tree of Chadian HDV.</p></caption><alt-text id="alt0005">Figure 3</alt-text><graphic xlink:href="gr3" id="celink0003"/><attrib>Isolates (367 nucleotides) and HDV genotypes 1 to 8 reference sequences retrieved from the GenBank database. The evolutionary history was inferred using the maximum likelihood method based on the Tamura 3-parameter (T92) model. Samples sequenced in this study are identified by the prefix TC. Reference sequences are identified by their accession number and country of origin. The numbers at each node correspond to the bootstrap values (&#x0003e;70%) obtained with 1000 replicates. HDV, hepatitis D virus.</attrib></fig></p><p id="para0028">Two patients (an 18-year-old pregnant woman and a 20-year-old male student) were both co-infected with the HBV-E and HDV-1 combination.</p><p id="para0029">The HBV and HDV nucleotide sequences generated from this study were deposited in the GenBank database accession numbers PQ252377- PQ252379 and PQ112532- PQ112537, respectively.</p></sec></sec><sec id="sec0015"><title>Discussion</title><p id="para0030">Co-infection of HBV and HDV poses a significant public health threat, and there is limited data on the prevalence of HDV in Chad. Therefore, this study sought to estimate the prevalence of HDV infection among pregnant women and students in Chad. Notwithstanding the small sample size used in this study, these populations are important because it is possible to limit the spread of infection through protective measures such as vaccination and transmission of mother to child. The seroprevalence of anti-HDV Ab was searched in a cohort of 94 individuals who tested positive for HBsAg, and molecular characterization of HBV and HDV was performed in the HBsAg-positive and HDV-positive samples.</p><p id="para0031">The overall prevalence of anti-HDV Ab in the HBsAg-positive cohort was 9.57%, which was low compared with the study carried out in N'Djamena hospitals, which reported an overall prevalence of 14% [<xref rid="bib0016" ref-type="bibr">16</xref>] but consistent with other reports from other African countries with a prevalence between 4% and 15% [<xref rid="bib0007" ref-type="bibr">7</xref>,<xref rid="bib0021" ref-type="bibr">21</xref>]. Our results show that Chad is an HDV-endemic country, which aligns with the report that most African countries have a high HDV endemicity [<xref rid="bib0007" ref-type="bibr">7</xref>]. The prevalence of anti-HDV Ab among pregnant women was higher (15.63% [5/32]) compared with students (6.45% [4/62]), although the difference was not significant (<italic>P</italic> = 0.265, 95% confidence interval 0.09-1.49). Nevertheless, this finding highlights that HDV infection in pregnant women might be a significant health problem, consistent with earlier reports [<xref rid="bib0022" ref-type="bibr">22</xref>,<xref rid="bib0023" ref-type="bibr">23</xref>].</p><p id="para0032">The prevalence of HDV antibodies rate of 15.63% among pregnant women in this study is consistent with the results of a study conducted in Gabon, which reported a prevalence of 15.6% in pregnant women [<xref rid="bib0024" ref-type="bibr">24</xref>] and another in Mauritania with 14.7% prevalence [<xref rid="bib0025" ref-type="bibr">25</xref>]. However, it is lower than the 20.63% reported in Pakistan [<xref rid="bib0026" ref-type="bibr">26</xref>] but higher than the 7.3% reported in Cameroon [<xref rid="bib0027" ref-type="bibr">27</xref>]. Similarly, the observed 6.45% HDV prevalence among students in this study compares to the 5.4% reported among Central African students [<xref rid="bib0028" ref-type="bibr">28</xref>]. It can also be said that students are younger and less often exposed to nosocomial contamination, which is often the mode of contamination for HDV [<xref rid="bib0025" ref-type="bibr">25</xref>].</p><p id="para0033">HDV RNA load was detected in 77.77% of anti-HDV-positive participants, of whom the majority had very low HBV DNA load. HBV DNA was detected in 55.32% of the HBsAg-positive individuals, confirming active HBV infection. Interestingly, only 87.5% of anti-HDV-positive participants also tested positive for HBV DNA. Moreover, HDV RNA was detected in 77.77% of anti-HDV-positive participant samples. These results are consistent with the available literature showing that HDV replication is found in approximately 50% of anti-HDV-positive participants and also agree with the assertion that HDV infection suppresses HBV replication [<xref rid="bib0002" ref-type="bibr">2</xref>]. These findings highlight the importance of testing for both HBV DNA and HDV RNA to accurately assess the status of HBV and HDV infection.</p><p id="para0034">HDV can be transmitted by drug injection practices, including poorly sterilized needles and medical instruments, re-use of disposable needles and syringes, history of transfusion, and unprotected sexual intercourse [<xref rid="bib0015" ref-type="bibr">15</xref>]. Although several of such risk factors for HDV infection were explored in this study, we did not find statistically significant associations between these factors and HDV seropositivity among our small sample size. This discovery may explain further why pregnant women were more likely to be HDV-positive compared with the students, with the hypothesis that the pregnant women were more likely to engage in unprotected sex compared with the students who, even if sexually active, do engage in protected sex. A second hypothesis can also be that students are younger and less often exposed to nosocomial contamination, which is often the mode of contamination for HDV. However, these hypotheses call for further research with a larger cohort for better exploration of the mentioned risks and other potential risk factors associated with HDV infection in Chad.</p><p id="para0035">All the HBV sequences generated in our study belonged to genotype E, which is found almost exclusively in Sub-Saharan Africa. HBV from our study clustered with HBV from neighboring countries (Sudan, Nigeria, and Cameroon), indicating the circulation of region-specific HBV genotypes. All the HDV sequences generated in our study belonged to the globally ubiquitous genotype 1. Interestingly, our sequences clustered into two distinct groups within HDV-1, comprising sequences isolated from the same country (Chad) or neighboring countries (Cameroon, Nigeria, CAR, and Gabon).</p><sec id="sec0016"><title>Limitations and future directions</title><p id="para0036">Our study was limited by the small sample size, which may affect the generalizability of the results. In addition, the retrospective nature of our study made it impossible to, unfortunately, get clinical data. Further research, including longitudinal studies with larger cohorts, is needed to better understand the epidemiology of HDV infection in Chad and to develop effective prevention and control strategies.</p></sec></sec><sec id="sec0017"><title>Conclusion</title><p id="para0037">Despite the small sample size, the results of this study confirm the high prevalence of HDV, particularly among pregnant Chadian women (&#x0003e;10%). In addition, HBV and HDV genotyping showed that HBV-E and HDV-1 circulate in this region as expected. Finally, a combination of genotypes of both viruses was found in young adults. This study reported a prevalence of HDV of 15.63% in pregnant women and 6.45% in students. HDV viral RNA was detectable in 77.77% of the participants. In Chad, there is certainly a need to test HBsAg-positive pregnant women for total antibodies against HDV, as positive ones might present more severe liver disease.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declarations of competing interest</title><p id="para0038">The authors have no competing interests to declare.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>Botelho-Souza</surname><given-names>LF</given-names></name><name><surname>Vasconcelos</surname><given-names>MPA</given-names></name><name><surname>dos Santos A de</surname><given-names>O</given-names></name><name><surname>Salcedo</surname><given-names>JMV</given-names></name><name><surname>Vieira</surname><given-names>DS</given-names></name></person-group><article-title>Hepatitis delta: virological and clinical aspects</article-title><source>Virol J</source><volume>14</volume><year>2017</year><fpage>177</fpage><pub-id pub-id-type="doi">10.1186/s12985-017-0845-y</pub-id><pub-id pub-id-type="pmid">28903779</pub-id>
</element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name><surname>Shirvani-Dastgerdi</surname><given-names>E</given-names></name><name><surname>Tacke</surname><given-names>F.</given-names></name></person-group><article-title>Molecular interactions between hepatitis B virus and delta virus</article-title><source>World J Virol</source><volume>4</volume><year>2015</year><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.5501/wjv.v4.i2.36</pub-id><pub-id pub-id-type="pmid">25964870</pub-id>
</element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name><surname>Caviglia</surname><given-names>GP</given-names></name><name><surname>Ciancio</surname><given-names>A</given-names></name><name><surname>Rizzetto</surname><given-names>M.</given-names></name></person-group><article-title>A review of HDV infection</article-title><source>Viruses</source><volume>14</volume><year>2022</year><fpage>1749</fpage><pub-id pub-id-type="doi">10.3390/v14081749</pub-id><pub-id pub-id-type="pmid">36016371</pub-id>
</element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Manns</surname><given-names>MP.</given-names></name></person-group><article-title>Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead</article-title><source>Nat Rev Gastroenterol Hepatol</source><volume>7</volume><year>2010</year><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2009.205</pub-id><pub-id pub-id-type="pmid">20051970</pub-id>
</element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Kamal</surname><given-names>H</given-names></name><name><surname>Fornes</surname><given-names>R</given-names></name><name><surname>Simin</surname><given-names>J</given-names></name><name><surname>St&#x000e5;l</surname><given-names>P</given-names></name><name><surname>Duberg</surname><given-names>AS</given-names></name><name><surname>Brusselaers</surname><given-names>N</given-names></name><etal/></person-group><article-title>Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies</article-title><source>J Viral Hepat</source><volume>28</volume><year>2021</year><fpage>1431</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1111/jvh.13577</pub-id><pub-id pub-id-type="pmid">34291520</pub-id>
</element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Ou</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection</article-title><source>J Infect Dis</source><volume>221</volume><year>2020</year><fpage>1677</fpage><lpage>1687</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz633</pub-id><pub-id pub-id-type="pmid">31778167</pub-id>
</element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name><surname>Stockdale</surname><given-names>AJ</given-names></name><name><surname>Chaponda</surname><given-names>M</given-names></name><name><surname>Beloukas</surname><given-names>A</given-names></name><name><surname>Phillips</surname><given-names>RO</given-names></name><name><surname>Matthews</surname><given-names>PC</given-names></name><name><surname>Papadimitropoulos</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis</article-title><source>Lancet Glob Health</source><volume>5</volume><year>2017</year><fpage>e992</fpage><lpage>e1003</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(17)30298-X</pub-id><pub-id pub-id-type="pmid">28911765</pub-id>
</element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name><surname>Lunel-Fabiani</surname><given-names>F</given-names></name><name><surname>Mansour</surname><given-names>W</given-names></name><name><surname>Amar</surname><given-names>AO</given-names></name><name><surname>Aye</surname><given-names>M</given-names></name><name><surname>Le Gal</surname><given-names>F</given-names></name><name><surname>Malick</surname><given-names>FZF</given-names></name><etal/></person-group><article-title>Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: A cross sectional study</article-title><source>J Infect</source><volume>67</volume><year>2013</year><fpage>448</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2013.06.008</pub-id><pub-id pub-id-type="pmid">23796871</pub-id>
</element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Takeshita</surname><given-names>Y</given-names></name><name><surname>Hutin</surname><given-names>YJF</given-names></name><name><surname>Harmanci</surname><given-names>H</given-names></name><name><surname>Easterbrook</surname><given-names>P</given-names></name><name><surname>Hess</surname><given-names>S</given-names></name><etal/></person-group><article-title>The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?</article-title><source>Arch Public Health</source><volume>79</volume><year>2021</year><fpage>180</fpage><pub-id pub-id-type="doi">10.1186/s13690-021-00693-2</pub-id><pub-id pub-id-type="pmid">34663473</pub-id>
</element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Le Gal</surname><given-names>F</given-names></name><name><surname>Brichler</surname><given-names>S</given-names></name><name><surname>Drugan</surname><given-names>T</given-names></name><name><surname>Alloui</surname><given-names>C</given-names></name><name><surname>Roulot</surname><given-names>D</given-names></name><name><surname>Pawlotsky</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Genetic diversity and worldwide distribution of the Deltavirus genus: a study of 2,152 clinical strains</article-title><source>Hepatology</source><volume>66</volume><year>2017</year><fpage>1826</fpage><lpage>1841</lpage><pub-id pub-id-type="doi">10.1002/hep.29574</pub-id><pub-id pub-id-type="pmid">28992360</pub-id>
</element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name><surname>Su</surname><given-names>CW</given-names></name><name><surname>Huang</surname><given-names>YH</given-names></name><name><surname>Huo</surname><given-names>TI</given-names></name><name><surname>Shih</surname><given-names>HH</given-names></name><name><surname>Sheen</surname><given-names>IJ</given-names></name><name><surname>Chen</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients</article-title><source>Gastroenterology</source><volume>130</volume><year>2006</year><fpage>1625</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2006.01.035</pub-id><pub-id pub-id-type="pmid">16697726</pub-id>
</element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name><surname>Sagnelli</surname><given-names>C</given-names></name><name><surname>Pisaturo</surname><given-names>M</given-names></name><name><surname>Curatolo</surname><given-names>C</given-names></name><name><surname>Codella</surname><given-names>AV</given-names></name><name><surname>Coppola</surname><given-names>N</given-names></name><name><surname>Sagnelli</surname><given-names>E.</given-names></name></person-group><article-title>Hepatitis B virus/hepatitis D virus epidemiology: changes over time and possible future influence of the SARS-CoV-2 pandemic</article-title><source>World J Gastroenterol</source><volume>27</volume><year>2021</year><fpage>7271</fpage><lpage>7284</lpage><pub-id pub-id-type="doi">10.3748/wjg.v27.i42.7271</pub-id><pub-id pub-id-type="pmid">34876788</pub-id>
</element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="book" id="sbref0013"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><part-title>Hepatitis D</part-title><year>2024</year><ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-d" id="interref0001">https://www.who.int/news-room/fact-sheets/detail/hepatitis-d</ext-link><comment>[accessed 15 March 2024]</comment></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name><surname>Khabir</surname><given-names>M</given-names></name><name><surname>Aliche</surname><given-names>AZ</given-names></name><name><surname>Sureau</surname><given-names>C</given-names></name><name><surname>Blanchet</surname><given-names>M</given-names></name><name><surname>Labont&#x000e9;</surname><given-names>P.</given-names></name></person-group><article-title>Hepatitis delta virus alters the autophagy process to promote its genome replication</article-title><source>J Virol</source><volume>94</volume><year>2020</year><pub-id pub-id-type="doi">10.1128/JVI.01936-19</pub-id><comment>e01936-19</comment></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Farci</surname><given-names>P</given-names></name><name><surname>Niro</surname><given-names>GA</given-names></name><name><surname>Zamboni</surname><given-names>F</given-names></name><name><surname>Diaz</surname><given-names>G.</given-names></name></person-group><article-title>Hepatitis D virus and hepatocellular carcinoma</article-title><source>Viruses</source><volume>13</volume><year>2021</year><fpage>830</fpage><pub-id pub-id-type="doi">10.3390/v13050830</pub-id><pub-id pub-id-type="pmid">34064419</pub-id>
</element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name><surname>Moussa</surname><given-names>AM</given-names></name><name><surname>Saleh</surname><given-names>TM</given-names></name><name><surname>Habkreo</surname><given-names>M</given-names></name><name><surname>Nadlaou</surname><given-names>B</given-names></name><name><surname>Ngare</surname><given-names>AA</given-names></name><name><surname>Stanislas</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Prevalence and predictors of viral hepatitis D co-infection in chronic HBsAg carriers</article-title><source>Open J Gastroenterol</source><volume>12</volume><year>2022</year><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.4236/ojgas.2022.129022</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name><surname>Debsikr&#x000e9;o</surname><given-names>N</given-names></name><name><surname>Mankr&#x000e9;o</surname><given-names>BL</given-names></name><name><surname>Mouk&#x000e9;net</surname><given-names>A</given-names></name><name><surname>Ouangkake</surname><given-names>M</given-names></name><name><surname>Mara</surname><given-names>N</given-names></name><name><surname>Moussa</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Prevalence of hepatitis B virus infection and its associated factors among students in N'Djamena, Chad</article-title><source>PLoS One</source><volume>19</volume><year>2024</year><object-id pub-id-type="publisher-id">e0273589</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0273589</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name><surname>Debsikr&#x000e9;o</surname><given-names>N</given-names></name><name><surname>Mankr&#x000e9;o</surname><given-names>BL</given-names></name><name><surname>Moukenet</surname><given-names>A</given-names></name><name><surname>Ndiaye</surname><given-names>AJS</given-names></name><name><surname>Diouf</surname><given-names>NL</given-names></name><name><surname>Lo</surname><given-names>G</given-names></name><etal/></person-group><article-title>Prevalence of hepatitis B and associated factors among pregnant women in N'Djamena, Chad</article-title><source>Fortune J Health Sci</source><volume>6</volume><year>2023</year><fpage>253</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.26502/fjhs.123</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><mixed-citation publication-type="other" id="sbref0019">s.r.o VA. GeneProof hepatitis B virus (HBV) PCR testing, <ext-link ext-link-type="uri" xlink:href="http://www.geneproof.com/geneproof-hepatitis-b-virus-hbv-pcr-kit/p1093" id="interref0002">http://www.geneproof.com/geneproof-hepatitis-b-virus-hbv-pcr-kit/p1093</ext-link>; 2024 [accessed 16 May 2024].</mixed-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Scholtes</surname><given-names>C</given-names></name><name><surname>Icard</surname><given-names>V</given-names></name><name><surname>Amiri</surname><given-names>M</given-names></name><name><surname>Chevallier-Queyron</surname><given-names>P</given-names></name><name><surname>Trabaud</surname><given-names>MA</given-names></name><name><surname>Rami&#x000e8;re</surname><given-names>C</given-names></name><etal/></person-group><article-title>Standardized one-step real-time reverse transcription-PCR assay for universal detection and quantification of hepatitis delta virus from clinical samples in the presence of a heterologous internal-control RNA</article-title><source>J Clin Microbiol</source><volume>50</volume><year>2012</year><fpage>2126</fpage><lpage>2128</lpage><pub-id pub-id-type="doi">10.1128/JCM.06829-11</pub-id><pub-id pub-id-type="pmid">22422856</pub-id>
</element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name><surname>Stockdale</surname><given-names>AJ</given-names></name><name><surname>Kreuels</surname><given-names>B</given-names></name><name><surname>Henrion</surname><given-names>MYR</given-names></name><name><surname>Giorgi</surname><given-names>E</given-names></name><name><surname>Kyomuhangi</surname><given-names>I</given-names></name><name><surname>de Martel</surname><given-names>C</given-names></name><etal/></person-group><article-title>The global prevalence of hepatitis D virus infection: systematic review and meta-analysis</article-title><source>J Hepatol</source><volume>73</volume><year>2020</year><fpage>523</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.04.008</pub-id><pub-id pub-id-type="pmid">32335166</pub-id>
</element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name><surname>Eyi</surname><given-names>ASA</given-names></name><name><surname>Komba</surname><given-names>OM</given-names></name><name><surname>Chambellant</surname><given-names>C</given-names></name><name><surname>Boussoukou</surname><given-names>IPM</given-names></name><name><surname>Moukambi</surname><given-names>L</given-names></name><name><surname>Moukambi</surname><given-names>KMWA</given-names></name><etal/></person-group><article-title>Triple burden of hepatitis B, hepatitis Delta viruses, and Plasmodium falciparum to pregnant women</article-title><source>IJID Reg</source><volume>13</volume><year>2024</year><object-id pub-id-type="publisher-id">100447</object-id><pub-id pub-id-type="doi">10.1016/j.ijregi.2024.100447</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name><surname>Ndzie Ondigui</surname><given-names>JL</given-names></name><name><surname>Mafopa Goumkwa</surname><given-names>N</given-names></name><name><surname>Lobe</surname><given-names>C</given-names></name><name><surname>Wandji</surname><given-names>B</given-names></name><name><surname>Awoumou</surname><given-names>P</given-names></name><name><surname>Voussou Djivida</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prevalence and risk factors of transmission of hepatitis delta virus in pregnant women in the Center Region of Cameroon</article-title><source>PLoS One</source><volume>19</volume><year>2024</year><pub-id pub-id-type="doi">10.1371/journal.pone.0287491</pub-id><comment>e0287491</comment></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name><surname>Makuwa</surname><given-names>M</given-names></name><name><surname>Caron</surname><given-names>M</given-names></name><name><surname>Souqui&#x000e8;re</surname><given-names>S</given-names></name><name><surname>Malonga-Mouelet</surname><given-names>G</given-names></name><name><surname>Mah&#x000e9;</surname><given-names>A</given-names></name><name><surname>Kazanji</surname><given-names>M.</given-names></name></person-group><article-title>Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus Clade 8 originates from and is endemic in Central Africa</article-title><source>J Clin Microbiol</source><volume>46</volume><year>2008</year><fpage>754</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1128/JCM.02142-07</pub-id><pub-id pub-id-type="pmid">18077651</pub-id>
</element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Mansour</surname><given-names>W</given-names></name><name><surname>Malick</surname><given-names>FZF</given-names></name><name><surname>Sidiya</surname><given-names>A</given-names></name><name><surname>Ishagh</surname><given-names>E</given-names></name><name><surname>Chekaraou</surname><given-names>MA</given-names></name><name><surname>Veillon</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prevalence, risk factors, and molecular epidemiology of hepatitis B and hepatitis delta virus in pregnant women and in patients in Mauritania</article-title><source>J Med Virol</source><volume>84</volume><year>2012</year><fpage>1186</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1002/jmv.23336</pub-id><pub-id pub-id-type="pmid">22711346</pub-id>
</element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name><surname>Aftab</surname><given-names>M</given-names></name><name><surname>Naz</surname><given-names>S</given-names></name><name><surname>Aftab</surname><given-names>B</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Rafique</surname><given-names>S</given-names></name><name><surname>Fatima</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Characterization of hepatitis delta virus among pregnant women of Pakistan</article-title><source>Viral Immunol</source><volume>32</volume><year>2019</year><fpage>335</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1089/vim.2019.0048</pub-id><pub-id pub-id-type="pmid">31553269</pub-id>
</element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name><surname>Ducancelle</surname><given-names>A</given-names></name><name><surname>Abgueguen</surname><given-names>P</given-names></name><name><surname>Birguel</surname><given-names>J</given-names></name><name><surname>Mansour</surname><given-names>W</given-names></name><name><surname>Pivert</surname><given-names>A</given-names></name><name><surname>Le Guillou-Guillemette</surname><given-names>H</given-names></name><etal/></person-group><article-title>High endemicity and low molecular diversity of hepatitis B virus infections in pregnant women in a rural district of North Cameroon</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><fpage>e80346</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0080346</pub-id><pub-id pub-id-type="pmid">24265811</pub-id>
</element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name><surname>Komas</surname><given-names>NP</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Abdou-Chekaraou</surname><given-names>M</given-names></name><name><surname>Pradat</surname><given-names>P</given-names></name><name><surname>Al Hawajri</surname><given-names>N</given-names></name><name><surname>Manirakiza</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults</article-title><source>PLOS Negl Trop Dis</source><volume>12</volume><year>2018</year><object-id pub-id-type="publisher-id">e0006377</object-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0006377</pub-id></element-citation></ref></ref-list><ack id="ack0001"><sec id="sec0018"><title>Funding</title><p id="para0039">This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></sec><sec id="sec0019"><title>Ethics approval and consent to participate</title><p id="para0040">This study was approved by the National Bioethics Committee in Chad on November 8, 2020 (201/PR/MESRI/DG/CNBT/2020), the UCAD Research Ethics Committee on December 7, 2021 (CER /UCAD/AD/MSN/050/2020), and the Ministry of Public Health and National Solidarity on February 18, 2021 (N&#x000b0;294/PR/MSPSN/SE/DGM/DGTPC /DPERO2021). Informed consent from all participants was obtained in accordance with the approval of the Chad National Bioethics Committee and the UCAD Research Ethics Committee. The objectives of the survey were presented to the participants. A unique anonymous study identifier number was assigned to every participant. Each participant had been informed of the results of their serology and advised on the measures to be taken. All experiments were performed in accordance with relevant guidelines and regulations.</p></sec><sec id="sec0020"><title>Acknowledgments</title><p id="para0041">The authors express their sincere thanks to Dr Isabelle CHEMIN, Cancer Research Centre INSERM U1052 of Lyon, for his help in quantifying the HDV viral load.</p></sec><sec id="sec0021"><title>Author contributions</title><p id="para0042">ND, FLF, AMM, and NCT, conceived the project; ND oversaw the data collection; ND, MD, OD GL, NL, MD, OD and IDO analyzed and interpreted the quantitative data, and, NL, GL, NAD and IDO, NAD, MNB, RMT and IC processed the sample. ND drafted the manuscript which was reviewed and validated by all authors who gave FLF the authority for publication.</p></sec></ack></back></article>